Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | UBE2N | P61088 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19217077 | 0.81 | MAOA (0.41) | KCNH2CYP2D6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18733991 | 0.77 | SIGMAR1 (0.34) | MEN1KMT2ANQO1MAPTTSHR | |
| SCHEMBL15701577 | 0.73 | MEN1 (0.40) | HRH3KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL18706485 | 0.72 | NOTUM (0.42) | HRH3KCNH2MEN1KMT2ANQO1 | |
| SCHEMBL2625759 | 0.71 | MEN1 (0.39) | HRH3KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL1101990 | 0.70 | MEN1 (0.55) | HRH3KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL9942876 | 0.70 | HRH3 (0.41) | HRH3KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL17169809 | 0.70 | NISCH (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL21145503 | 0.70 | CYP2D6 (0.46) | HRH3KCNH2CYP2D6KMT2AHTR2B | |
| SCHEMBL17930593 | 0.70 | SIGMAR1 (0.57) | HRH3KCNH2CYP2D6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019006291-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2019006295-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 503/4885KCNH2 3944/4885CYP2D6 601/4885 |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HRH3 517/4885KCNH2 3852/4885CYP2D6 512/4885 |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 503/4885KCNH2 3944/4885CYP2D6 601/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 517/4885KCNH2 3852/4885CYP2D6 512/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HRH3 503/4885KCNH2 3944/4885CYP2D6 601/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 503/4885KCNH2 3944/4885CYP2D6 601/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HRH3 503/4885KCNH2 3944/4885CYP2D6 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.